Drug & intervention
testosterone cypionate
RxCUI 835827
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
17 shownSupraphysiologic Testosterone Priming Induces Darolutamide Extended ResponseNCT07142551 · 2026-03-09
RECRUITINGThe COSMYC Trial (COmbined Suppression of MYC)NCT06922318 · 2025-08-19
RECRUITINGSupraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA StudyNCT06039371 · 2024-05-21
RECRUITINGSipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPCNCT06100705 · 2023-12-20
RECRUITINGDifluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate CancerNCT06059118 · 2023-10-04
RECRUITINGSequential Testosterone and Enzalutamide Prevents Unfavorable ProgressionNCT04363164 · 2020-08-19
RECRUITINGTesting the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate CancerNCT07852195 · 2027-01-06
NOT_YET_RECRUITINGTestosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active SurveillanceNCT07278362 · 2026-08-31
NOT_YET_RECRUITINGBipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate CancerNCT06305598 · 2024-12-19
ACTIVE_NOT_RECRUITINGExtreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)NCT04558866 · 2021-06-09
COMPLETEDBiomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen TherapyNCT04424654 · 2020-09-22
COMPLETEDCOMbination of Bipolar Androgen Therapy and NivolumabNCT03554317 · 2018-09-05
COMPLETEDTestosterone and Olaparib in Treating Patients With Castration-Resistant Prostate CancerNCT03516812 · 2018-08-29
COMPLETEDSex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate CancerNCT02995330 · 2017-02-09
TERMINATEDTestosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide ResistanceNCT02286921 · 2015-01-01
COMPLETEDRE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)NCT02090114 · 2014-08-25
COMPLETEDBipolar Androgen-based Therapy for Prostate Cancer (BAT)NCT01750398 · 2013-01-01
COMPLETEDConditions being studied
Prostate Cancer7Castration-Resistant Prostate Carcinoma3Metastatic Castration-resistant Prostate Cancer3Stage IVB Prostate Cancer AJCC v83Castration Resistant Metastatic Prostate Cancer2Castration-resistant Prostate Cancer1Hypogonadism, Male1Metastatic Castration-Resistant Prostate Adenocarcinoma1Metastatic Prostate Adenocarcinoma1Metastatic Prostate Cancer1Metastatic Prostate Carcinoma1Prostate Adenocarcinoma1Recurrent Prostate Cancer1
Research locations
BaltimoreMaryland, United States9SeattleWashington, United States4BostonMassachusetts, United States2OmahaNebraska, United States2Porto AlegreRio Grande do Sul, Brazil2Washington D.C.District of Columbia, United States2Ann ArborMichigan, United States1AtlantaGeorgia, United States1AuroraColorado, United States1BirminghamAlabama, United States1BuffaloNew York, United States1ChicagoIllinois, United States1
Leading sponsors
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.